Paper41847148
Nanotechnology-based targeted delivery strategies for the treatment of Alzheimer's disease.
Yuan X and 2 others. Nanoscale Adv, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Nanotechnology-based targeted delivery strategies for the treatment of Alzheimer's disease. Papers, record 41847148. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41847148
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nanotechnology-based targeted delivery strategies for the treatment of Alzheimer's disease.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References156
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34046943 | Traceable Nano-Biohybrid Complexes by One-Step Synthesis as CRISPR-Chem Vectors for Neurodegenerative Diseases Synergistic Treatment. | Adv Mater | 2021 | https://conductscience.org/library/papers/34046943 | PubMed |
| 2 | 28734741 | Beneficial effects of TQRF and TQ nano- and conventional emulsions on memory deficit, lipid peroxidation, total antioxidant status, antioxidants genes expression and soluble Aβ levels in high fat-cholesterol diet-induced rats. | Chem Biol Interact | 2017 | https://conductscience.org/library/papers/28734741 | PubMed |
| 3 | 31775806 | Autophagy protein NRBF2 has reduced expression in Alzheimer's brains and modulates memory and amyloid-beta homeostasis in mice. | Mol Neurodegener | 2019 | https://conductscience.org/library/papers/31775806 | PubMed |
| 4 | 37183523 | The amyloid cascade hypothesis: an updated critical review. | Brain | 2023 | https://conductscience.org/library/papers/37183523 | PubMed |
| 5 | 35897815 | Boron Nitride Nanoparticles Loaded with a Boron-Based Hybrid as a Promising Drug Carrier System for Alzheimer's Disease Treatment. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35897815 | PubMed |
| 6 | 35456590 | Intranasal Cerium Oxide Nanoparticles Ameliorate Cognitive Function in Rats with Alzheimer's via Anti-Oxidative Pathway. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35456590 | PubMed |
| 7 | 28698078 | Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer's disease: In vitro and in vivo evaluation. | Int J Biol Macromol | 2017 | https://conductscience.org/library/papers/28698078 | PubMed |
| 8 | 37075744 | Study on the Role of an Erythrocyte Membrane-Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/37075744 | PubMed |
| 9 | 36632961 | Novel naringin tablet formulations of agro-resides based nano/micro crystalline cellulose with neuroprotective and Alzheimer ameliorative potentials. | Int J Biol Macromol | 2023 | https://conductscience.org/library/papers/36632961 | PubMed |
| 10 | 30603085 | Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis. | Transl Neurodegener | 2018 | https://conductscience.org/library/papers/30603085 | PubMed |
| 11 | 39389804 | Emerging roles of antimicrobial peptides in innate immunity, neuronal function, and neurodegeneration. | Trends Neurosci | 2024 | https://conductscience.org/library/papers/39389804 | PubMed |
| 12 | 30504054 | A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer's disease. | J Photochem Photobiol B | 2019 | https://conductscience.org/library/papers/30504054 | PubMed |
| 13 | 35839463 | Cholinergic Neuron Targeting Nanosystem Delivering Hybrid Peptide for Combinatorial Mitochondrial Therapy in Alzheimer's Disease. | ACS Nano | 2022 | https://conductscience.org/library/papers/35839463 | PubMed |
| 14 | 26440073 | GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease. | ACS Nano | 2015 | https://conductscience.org/library/papers/26440073 | PubMed |
| 15 | 15322526 | Strategies for disease modification in Alzheimer's disease. | Nat Rev Neurosci | 2004 | https://conductscience.org/library/papers/15322526 | PubMed |
| 16 | 37947289 | Macrophage Membrane-Modified MoS2 Quantum Dots as a Nanodrug for Combined Multi-Targeting of Alzheimer's Disease. | Adv Healthc Mater | 2024 | https://conductscience.org/library/papers/37947289 | PubMed |
| 17 | 33793837 | Anti-Aβ-scFv-loaded polymeric nano-micelles with enhanced plasma stability. | J Pharm Pharmacol | 2021 | https://conductscience.org/library/papers/33793837 | PubMed |
| 18 | 34727550 | The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer's Disease Rat Model. | Neuropsychobiology | 2022 | https://conductscience.org/library/papers/34727550 | PubMed |
| 19 | 35278428 | Box-Behnken design optimized silibinin loaded glycerylmonooleate nanoliquid crystal for brain targeting. | Chem Phys Lipids | 2022 | https://conductscience.org/library/papers/35278428 | PubMed |
| 20 | 30691325 | Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. | J Drug Target | 2019 | https://conductscience.org/library/papers/30691325 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980730 | From molecular pathways to nanocarrier design: a translational framework for lipid-based nanoparticles in Alzheimer's disease. | Discov Nano | 2026 | https://conductscience.org/library/papers/42980730 | PubMed |
| 42764330 | Targeting the BACE1-GSK-3β Signaling Axis in Alzheimer's Disease: From Molecular Crosstalk to Nanotechnology-Based Translational Strategies. | Mol Neurobiol | 2026 | https://conductscience.org/library/papers/42764330 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACHE | 43 | PubTator's text mining | https://conductscience.org/library/genes/43 | NCBI Gene |
| APP | 351 | PubTator's text mining | https://conductscience.org/library/genes/351 | NCBI Gene |
| BCHE | 590 | PubTator's text mining | https://conductscience.org/library/genes/590 | NCBI Gene |
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IL1A | 3552 | PubTator's text mining | https://conductscience.org/library/genes/3552 | NCBI Gene |
| MAPT | 4137 | PubTator's text mining | https://conductscience.org/library/genes/4137 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41847148
GET https://conductscience.org/api/papers/v1/41847148/references?page=2